Novartis Ag ADR (NVS) Stock Price, Quote & News

Company Profile

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CD...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 41 61 324 11 11

Fax: 41 61 324 78 26

Website: www.novartis.com

Address:

Lichtstrasse 35, Basel, Switzerland

55X_ROI_Q1_2026 May. 15 at 9:01 PM

$SLS GPS P3 Results are worth - truly worth $40B + the Instant the REGAL Results are announced - GPS MOS 30 - 36 months, BAT 8-10 --- T1 Trading Halt - Gap Up into the $10B MCap Range / $50 Per Share Range - AND CLIMBING And to Bottom LINE 009 / TAMBICICLIB Will Be FDA Approved - the Market Has yet to appreciate its value. Gleevc - Imatinib Imbrutinib - Imbruvica Upadactinib - Rinvoq Upadactinib <- say that 3 x fast $PFE Pfizers' Ibrance - Palbociclib CDKinase Inhibitor $NVS Novartis' Kisqali -Ribociclib CDKinase Inhibitor $LLY Eli Lilly's Verzenio - Abemaciclib CDKinase Inhibitor $SLS ufTambiciclib CDKInase Inhibitor. https://www.reddit.com/r/sellasLifescience/search/?q=aml-mr&cId=057d1aab-2b7d-4bf0-a2d4-c3227af101f8&iId=8d5110f2-0189-40ea-bc04-b363b5cad724 for anyone interested in DD/ i been here invested a long time/ if you have an interest in understanding why 009 / Gps these SLS Shares are trading / short / warrant manipulative share price management -reality is GPS P3 Results are now Imminent and - truly worth $40B + the moment the REGAL Trial Results are announced.

0 · Reply

Quantumup May. 15 at 3:13 PM

Stifel⬆️the PT on $CELC to $175 (was $150) and reiterated at Buy on the inclusion of 1L ET-sensitive revenue estimates (+$4B to peak). $RLAY AZN PFE RHHBY BGNE OTSKY $NVS Here's what Stifel said in its note to investors: https://x.com/Quantumup1/status/2055304961156665573?s=20

0 · Reply

trenddetector May. 14 at 3:30 PM

$NVS Kisqali (ribociclib) is quietly becoming one of the most important drugs in breast cancer. Five-year data from the NATALEE trial showed a 28.4% reduction in cancer recurrence risk for HR+/HER2- early breast cancer patients — and that benefit held up even after the 3-year treatment period ended. That's a big deal — because early breast cancer patients are always asking "what are the odds it comes back?" Kisqali gives them a real answer. The safety profile at the 400mg dose was well tolerated, with most discontinuations driven by lab findings rather than how patients felt. Kisqali is featured on YourCancerPath.com — free, no-login cancer navigation for patients and families. 🔗 YourCancerPath.com #NVS #breastcancer #Kisqali

0 · Reply

Quantumup May. 14 at 10:34 AM

Citizens⬇️ $AVTX's PT to $55 and reiterated at a Market Outperform rating. $ABBV MLTX SLRN UCBJY INCY $NVS Citizens said in its note: Positive Phase 2 LOTUS results support advancement to registrational studies; we reiterate our Market Outperform rating on Avalo Therapeutics though lower our risk-adjusted, DCF-derived price target to $55 from $62 to reflect the recent equity financing. This morning, Avalo reported 1Q26 financial results and business updates, underscoring its plans to advance abdakibart into registrational Phase 3 studies. Recall, the Phase 2 LOTUS trial demonstrated positive results (our note here) with, in our view, a robust and competitive magnitude of benefit. The company ended 1Q26 with $82MM in cash, and raised net proceeds of ~$40MM from the equity offering that followed the announcement of Phase 2 results.

0 · Reply

Charlie_Omaha May. 13 at 3:55 PM

$IOVA If any, Trump policies of Made in USA and Most Favored Nation rules make this an attractive candidate for $AZN $NVS $TAK as it counts as US plant and manufacturing, and accumulated debt as tax savings. Fred and Wayne are idiots.

0 · Reply

Charlie_Omaha May. 13 at 2:42 PM

$IOVA Amazing potential and excellent cures. Horrible management. For the sake of patients, hand the company to capable hands of $MRK or $NVS Fred and Wayne can't execute. Too incompetent. $10 A share and $15 future milestone commercialization linked payments. No more dilution is a bonus.

0 · Reply

Quantumup May. 12 at 7:08 PM

Guggenheim y'day🏁 $ELVN Buy; $80—its PT is supported by conservative assumptions for ELVN-001 (75% PoS in 2L CML, 50% peak shr, 25% PoS in 1L CML, 20% peak shr)= $2.9B risk-adj'd US peak sales in 2043—up to $5B peak. TERN - $MRK $NVS Here's what Guggenheim said in its initiation report: https://x.com/Quantumup1/status/2054276939058176483?s=20

0 · Reply

nnnuuu May. 12 at 5:42 PM

$NVS news soon on lp(a)horizon?

0 · Reply

Quantumup May. 12 at 11:55 AM

Stephens🏁 $PVLA OW; $220, and said, (Q)TORIN' Through Rare Skin Diseases; Initiating OW/Vol. $TARA $NVS PFE Here's what else Stephens said in its initiation report: https://x.com/Quantumup1/status/2054167804635382106?s=20

0 · Reply

Fingerlickengood May. 11 at 12:42 PM

$CDXS $NVS Especially after considering Codexis’ existing partnerships in India for enzymatic drug manufacturing! https://www.globenewswire.com/news-release/2021/10/18/2315614/24825/en/codexis-almelo-and-rc2-announce-a-tri-party-collaboration-for-the-enzymatic-production-of-low-cost-sitagliptin-api-for-the-generic-market-including-a-license-to-codexis-enzyme-tech.html

1 · Reply

Market Cap	282.56B
Revenue (ttm)	56.67B
Net Income (ttm)	13.98B
EPS (ttm)	N/A
PE Ratio	17.23
Forward PE	16.93
Profit Margin	24.67%
Debt to Equity Ratio	1.16

Volume	829,300
Avg Vol	1,715,068
Day's Range	N/A - N/A
Shares Out	1.91B
Stochastic %K	57%
Beta	0.46
Analysts	Sell
Price Target	$147.95